INJE PharmacoGenomics Research Center

· Oh MK, Lee HC, Kim SU, Kim BT, Song GS, Shin JG, Ghim JL

Evaluation of pharmacokinetic drug-drug interaction between tegoprazan and clarithromycin in healthy subjects (cPMTb)

Transl Clin Pharmacol. 31(2):114-123 / 2023.06 [LINK]

· Kim RH, Jayanti RP, Lee HY, Kim HK, Kang JY, Park IN, Kim JH, Oh JY, Kim HW, Lee HY, Ghim JL, Ahn SZ, Long NP, Cho YS, Shin JG, On Behalf Of The cPMTb

Development of a population pharmacokinetic model of pyrazinamide to guide personalized therapy: impacts of geriatric and diabetes mellitus on clearance (cPMTb)

Front Pharmacol. 26:14:1116226 / 2023.05 [LINK]

· Yen NTH, Oh JH, Anh NTV, Le QV, Park SM, Park YJ, Cho YS, Moon KS, Nguyen HT, Shin JG, Long NP

Systems-level multi-omics characterization provides novel molecular insights into indomethacin toxicity (cPMTb)

Chem Biol Interact. 25:375:110430 / 2023.04 [LINK]

· Cho HY, Ahn SZ, Cho YS, Seo SK, Kim DH, Shin JG, Lee SJ

CYP2C19 Contributes to THP-1-Cell-Derived M2 Macrophage Polarization by Producing 11,12- and 14,15-Epoxyeicosatrienoic Acid, Agonists of the PPARγ Receptor (cPMTb)

Pharmaceuticals(Basel). 16(4):593 / 2023.04 [LINK]

· Soedarsono S, Jayanti RP, Mertaniasih NM, Kusmiati T, Permatasari A, Indrawanto DW, Charisma AN, Lius EE, Yuliwulandari R, Hoa PQ, Phat NK, Thu VTA, Anh NK, Ahn SZ, Long NP, Cho YS, Shin JG

Development of population pharmacokinetics model and Bayesian estimation of rifampicin exposure in Indonesian patients with tuberculosis (cPMTb)

Tuberculosis (Edinb). 139:102325 / 2023.03 [LINK]

· Thu VTA, Dat LD, Jayanti RP, Trinh HKT, Hung TM, Cho YS, Long NP, Shin JG

Advancing personalized medicine for tuberculosis through the application of immune profiling (cPMTb)

Front Cell Infect Microbiol. 10:13:1108155 / 2023.02 [LINK]

· Anh NK, Phat NK, Yen NTH, Jayanti RP, Thu VTA, Park YJ, Cho YS, Shin JG, Kim DH, Oh JY, Long NP

Comprehensive lipid profiles investigation reveals host metabolic and immune alterations during anti-tuberculosis treatment: Implications for therapeutic monitoring (cPMTb)

Biomed Pharmacother. 158:114187 / 2023.02 [LINK]

· Anh NK, Tung PM, Kim MJ, Long NP, Cho YS, Kim DH, Shin JG

Quantitative Analysis of Isoniazid and Its Four Primary Metabolites in Plasma of Tuberculosis Patients Using LC-MS/MS (cPMTb)

Molecules. 27(23):8607 / 2022.12 [LINK]

· Sidamo T, Rao PS, Aklillu E, Shibeshi W, Park YM, Cho YS, Shin JG, Heysell SK, Mpagama SG, Engidawork E

Population Pharmacokinetics of Levofloxacin and Moxifloxacin, and the Probability of Target Attainment in Ethiopian Patients with Multidrug-Resistant Tuberculosis (cPMTb)

Infect Drug Resist. 28:15:6839-6852 / 2022.11 [LINK]

· Yen NTH, Park SM, Thu VTA, Phat NK, Cho YS, Yoon SJ, Shin JG, Kim DH, Oh JH, Long NP

Genome-wide gene expression analysis reveals molecular insights into the drug-induced toxicity of nephrotoxic agents (cPMTb)

Life Sci. 1:306:120801 / 2022.10 [LINK]

Publications

Product